- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00112840
CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer
A Phase I/II Trial of CCI-779 and Bevacizumab in Stage IV Renal Cell Carcinoma
Study Overview
Status
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To determine the maximally tolerated dose (MTD) and recommended dosing for the combination of CCI-779 and Bevacizumab in patients with metastatic renal cell cancer. (Phase I) II. To determine the proportion of patients with metastatic renal cell cancer who are progression free at 6 months. (Phase II)
SECONDARY OBJECTIVES:
I. To determine the toxicity of the combination of CCI 779 and Bevacizumab in patients with metastatic renal cell cancer. (Phase II) II. To determine the clinical response rate of CCI 779 and Bevacizumab in patients with metastatic renal cell cancer. (Phase II) III. To determine the time to progression (TTP), disease free survival, and overall survival of CCI 779 and Bevacizumab in patients with metastatic renal cell cancer. (Phase II)
TERTIARY OBJECTIVES:
I. To identify predictive molecular markers of response, both at the tumor level and in the plasma/serum level, in an exploratory manner.
II. To correlate blood markers of angiogenesis with clinical activity of the combination of CCI-779 and Bevacizumab.
OUTLINE: This is a multicenter, phase I dose-escalation study followed by a phase II study. Patients are stratified according to study phase (I vs II).
Phase I: Patients receive CCI-779 IV on days 1, 8, 15, and 22 and bevacizumab IV on days 1 and 15.
Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of CCI-779 and bevacizumab until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Phase II: Patients receive CCI-779 and bevacizumab as in phase I at the MTD determined in phase I. After completion of study treatment, patients are followed every 3 months until disease progression and then every 6 months for up to 3 years after study entry.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- University of Wisconsin Hospital and Clinics
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Histologically confirmed metastatic or unresectable renal cell cancer
- Must have a component of conventional clear cell histology
The following histologies are excluded:
- True papillary
- Sarcomatoid features without any clear cell component
- Chromophobe
- Oncocytoma
- Collecting duct tumors
- Transitional cell carcinoma
- Measurable disease, defined as ≥ 1 lesion ≥ 2.0 cm in the longest diameter by conventional techniques OR ≥ 1.0 cm by spiral CT scan
- Tumor tissue (from primary tumor or metastases) available AND patient is willing to donate blood for research studies (phase II only)
- No CNS metastases by head CT scan or MRI
- Performance status - ECOG 0-2
- Absolute neutrophil count ≥ 1,500/mm^3
- Platelet count ≥ 100,000/mm^3
- Hemoglobin ≥ 9.0 g/dL
- No evidence of bleeding diathesis or coagulopathy
- No history of clinically significant bleeding or active bleeding
- Bilirubin ≤ 1.5 times upper limit of normal (ULN)
- Alkaline phosphatase ≤ 2.5 times ULN (5 times ULN if liver metastases are present)
- AST ≤ 2.5 times ULN (5 times ULN if liver metastases are present)
PT/INR ≤ 1.5
- Patients on full-dose warfarin or stable-dose low molecular weight heparin must have INR > 1.5 but ≤ 3
- Creatinine ≤ 1.5 times ULN
- Urine protein ≤ 1+ by dipstick or urinalysis
- Urine protein < 1,000 mg on a 24-hour urine collection
- No cerebrovascular accident within the past 6 months
- No peripheral vascular disease with claudication on < 1 block
- No New York Heart Association class II-IV congestive heart failure
- No angina pectoris requiring nitrate therapy
- No myocardial infarction within the past 6 months
- No uncontrolled hypertension, defined as systolic blood pressure (BP) ≥ 160 mm Hg and/or diastolic BP ≥ 90 mm Hg despite medication
- No cardiac arrhythmias
- No other significant cardiovascular disease
- No ongoing hemoptysis
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for at least 3-4 months after study participation
- Fasting cholesterol ≤ 350 mg/dL
- Triglycerides ≤ 1.5 times ULN (may achieve using lipid lowering agents)
- No known hypersensitivity to recombinant human antibodies
- No significant traumatic injury within the past 4 weeks
- No serious or non-healing wound, ulcer, or bone fracture
- No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 4 weeks
- No pathological conditions that confer a high risk of bleeding (e.g., tumor involving major vessels or known varices)
- No diabetes
No other currently active malignancy except nonmelanoma skin cancer
- Patients are not considered to have a currently active malignancy if they have completed anticancer therapy AND are considered to be at < 30% risk of relapse
- No other uncontrolled serious medical or psychiatric condition
- At least 4 weeks since prior biologic response modifiers for metastatic disease
- No prior bevacizumab or mTOR inhibitors
- At least 4 weeks since prior chemotherapy for metastatic disease
- Prior palliative radiotherapy to metastatic lesions allowed provided there is ≥ 1 measurable and/or evaluable lesion that has not been irradiated
- At least 4 weeks since prior and no concurrent radiotherapy
- Prior nephrectomy allowed
- More than 4 weeks since prior major surgery or open biopsy
- More than 1 week since prior core biopsy
- No concurrent major surgery
At least 4 weeks (2 weeks for vascular endothelial growth factor [VEGF] receptor tyrosine kinase inhibitor [RTKI] therapy) since prior and no more than 2 therapies (phase II)
- One of these therapies must have included a RTKI agent administered for a minimum of 4 weeks
- Concurrent full-dose warfarin or low molecular weight heparin allowed provided dose is stable AND INR requirements are met
- Concurrent zoledronate for bone metastases and/or hypercalcemia allowed provided therapy was initiated prior to study entry
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: CCI-779 and bevacizumab
Patients receive CCI-779 IV on days 1, 8, 15, and 22 and bevacizumab IV on days 1 and 15.
Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of CCI-779 and bevacizumab until the maximum tolerated dose (MTD) is determined.
The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
Phase II patients receive CCI-779 and bevacizumab as in phase I at the MTD determined in phase I.
After completion of study treatment, patients are followed every 3 months until disease progression and then every 6 months for up to 3 years after study entry.
|
CCI-779 is taken IV on days 1, 8, 15, 22 of a 28-day cycle.
Dose level is dependent on phase.
Other Names:
Bevacizumab is taken IV on Days 1 and 15 of a 28-day cycle.
Dose Level determined by phase.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose-limiting Toxicity (DLT) (Phase I)
Time Frame: Patients observed a minimum of 4 weeks (one full course). The maximum number of cycles observed was 16 cycles.
|
For this protocol, dose limiting toxicity (DLT) will be defined as an adverse event attributed (definitely, probably, or possibly) to the study treatment in the first four weeks of combination therapy, and meeting the following criteria:
The maximum tolerated dose level (MTD) will be defined as the highest safely tolerated dose where 1 or 0 out of 6 patients experience DLT with the next higher dose. |
Patients observed a minimum of 4 weeks (one full course). The maximum number of cycles observed was 16 cycles.
|
Proportion of Progression-free Patients at 6 Months (Phase II)
Time Frame: 6 months after study entry
|
Determination of progression will be made according to Response Evaluation Criteria in Solid Tumors (RECIST).
A progression (PD) is defined as having at least a 20% increase in the sum of the longest dimension of target lesions taking as reference the smallest sum of the largest dimension recorded at baseline.The proportion of progression-free patients will be estimated by the number of successes divided by the total number of evaluable patients.
Ninety-five percent confidence intervals for the success proportion will be calculated.
All patients meeting the eligibility criteria who have signed a consent form and begun treatment will be considered evaluable.
Those who die will be considered to have had disease progression unless documented evidence clearly indicates no progression has occurred.
|
6 months after study entry
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Best Response Rate of CCI-779 and Bevacizumab in Patients With Metastatic Renal Cell (Phase II)
Time Frame: Up to 3 years from study registration
|
The number of participants with clinical tumor response to treatment will be evaluated using the Response Evaluation Criteria In Solid Tumors (RECIST). Complete Response (CR): Disappearance of all target lesions Partial Response (PR): At least a 30% decrease in the sum of the largest dimension (LD) of target lesions taking as reference the baseline sum LD. |
Up to 3 years from study registration
|
Time to Progression (Phase II)
Time Frame: Up to 3 years from study registration
|
The time to progression is defined as the time from registration to the time of progression.
Those who die will be considered to have had disease progression unless documented evidence clearly indicates no progression has occurred.
The distribution of time to progression will be estimated using the method of Kaplan-Meier.
|
Up to 3 years from study registration
|
Overall Survival (Phase I and II)
Time Frame: Up to 3 years from study registration
|
The overall survival or survival time is defined as the time from registration to death due to any cause.
The distribution of overall survival will be estimated using the method of Kaplan-Meier.
|
Up to 3 years from study registration
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jaime Merchan, Mayo Clinic
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Kidney Neoplasms
- Carcinoma, Renal Cell
- Carcinoma
- Physiological Effects of Drugs
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Bevacizumab
Other Study ID Numbers
- NCI-2009-00109 (REGISTRY: CTRP (Clinical Trial Reporting Program))
- N01CM62205 (U.S. NIH Grant/Contract)
- 6986 (Registry Identifier: South African Clinical Trials Registry (SANCTR))
- CDR0000428311
- NCI-6986
- MC0452 (OTHER: Mayo Clinic)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Clear Cell Renal Cell Carcinoma
-
Celldex TherapeuticsTerminatedKidney Neoplasms | Metastatic Renal Cell Carcinoma | Ovarian Clear Cell Carcinoma | Papillary Renal Cell Carcinoma | Renal Cell Carcinoma (RCC) | Clear-cell Renal Cell CarcinomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Unresectable Renal Cell... and other conditionsUnited States
-
Guru SonpavdePfizer; Hoosier Cancer Research NetworkWithdrawnKidney Cancer | Clear-cell Renal Cell Carcinoma | RCC | Clear-cell Kidney CarcinomaUnited States
-
Peloton Therapeutics, Inc.Active, not recruitingA Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)Kidney Cancer | Clear Cell Renal Cell Carcinoma | Glioblastoma | Solid Tumor | Glioblastoma Multiforme | Advanced Solid Tumors | GBM | Solid Tumor, Adult | Solid Carcinoma | Glioblastoma, Adult | ccRCC | RCC, Clear Cell Adenocarcinoma | RCC | Renal Cell Carcinoma, Metastatic | Renal Cell Carcinoma Recurrent | Renal Cell...
-
Queen Mary University of LondonAstraZeneca; Vall d'Hebron Institute of OncologyActive, not recruitingRenal Clear Cell Carcinoma | Renal Papillary Cell CarcinomaUnited Kingdom
-
AmgenCompletedRenal Cell Carcinoma | Clear Cell Renal Cell Carcinoma | Clear Cell Renal Carcinoma | Renal Cell AdenocarcinomaFrance, United States, Germany
-
University of WashingtonMerck Sharp & Dohme LLC; Prometheus LaboratoriesTerminatedMetastatic Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer | Advanced Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell CancerUnited States
-
Telix International Pty LtdGrand Pharmaceutical (China) Co., Ltd.CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Cancer | Suspected Recurrent Renal Clear Cell CarcinomaChina
-
M.D. Anderson Cancer CenterActive, not recruitingMetastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8United States
-
Association Pour La Recherche des Thérapeutiques...CompletedClear-cell Metastatic Renal Cell Carcinoma | Clear-cell Renal CarcinomaFrance
Clinical Trials on CCI-779
-
National Cancer Institute (NCI)CompletedRecurrent Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7United States
-
National Cancer Institute (NCI)National Comprehensive Cancer NetworkCompletedRecurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue SarcomaUnited States
-
National Cancer Institute (NCI)CompletedAdult Solid NeoplasmUnited States
-
National Cancer Institute (NCI)CompletedRhabdomyosarcoma | Recurrent Osteosarcoma | Recurrent Childhood Rhabdomyosarcoma | Previously Treated Childhood Rhabdomyosarcoma | Recurrent Childhood Soft Tissue Sarcoma | Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Childhood Angiosarcoma | Childhood Epithelioid Sarcoma | Childhood... and other conditionsUnited States, Canada
-
National Cancer Institute (NCI)CompletedProstate Adenocarcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate CancerUnited States
-
National Cancer Institute (NCI)CompletedMalignant NeoplasmUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Osteosarcoma | Metastatic Osteosarcoma | Recurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue SarcomaUnited States, Canada
-
National Cancer Institute (NCI)CompletedAdult Anaplastic Astrocytoma | Adult Anaplastic Oligodendroglioma | Adult Diffuse Astrocytoma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Adult Mixed Glioma | Adult Oligodendroglioma | Recurrent Adult Brain NeoplasmUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Marginal Zone Lymphoma | Waldenstrom Macroglobulinemia | Recurrent Adult Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Follicular Lymphoma | Recurrent Lymphoplasmacytic Lymphoma | AIDS-Related Hodgkin LymphomaUnited States
-
National Cancer Institute (NCI)CompletedCixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast CancerRecurrent Breast Carcinoma | Male Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7United States